Carisma Therapeutics, Inc. (CARM)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Biotechnology	19.63M	14.92M	9.83M
Biotechnology Growth	31.59%	51.71%	-
Total	19.63M	14.92M	9.83M
Total Growth	31.59%	51.71%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
United States	19.63M	14.92M	9.83M
United States Growth	31.59%	51.71%	-
Total	19.63M	14.92M	9.83M
Total Growth	31.59%	51.71%	-

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 15, 2026

Data Sources Report a data error